Sex-based disparities in cardiovascular outcomes: real-world evidence following chimeric antigen receptor T-cell therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Gender Differences in Cardiovascular Outcomes After Chimeric Antigen Receptor T-Cell Therapy: Insights from Real-World Data

  • By

  • Abdul Rasheed Bahar

  • Yasemin Bahar

  • Paawanjot Kaur

  • Nagasai Yalavarthi

  • Ali Awad

  • Shaheena Raheem

  • Ahmet Afsin Oktay

  • July 8, 2026

Share

  • 1

    The study evaluated sex-based differences in major adverse cardiovascular events (MACE) following CAR-T therapy using real-world data.

  • 2

    Among 4,944 matched patients, males had a higher incidence of MACE compared to females at both 1 and 2 years post-CAR-T therapy.

  • 3

    At 1 year, the risk ratio for MACE in males was 1.22, and at 2 years, it was 1.15, indicating a persistent higher risk.

  • 4

    Males also exhibited higher all-cause mortality and increased risks of arrhythmias and conduction abnormalities at 2 years.

  • 5

    The findings suggest the need for incorporating biological sex into cardiovascular risk assessment in CAR-T therapy patients.

Original Source(s)

Sex-based disparities in cardiovascular outcomes: real-world evidence following chimeric antigen receptor T-cell therapy

  • by Abdul Rasheed Bahar, Yasemin Bahar, Paawanjot Kaur, Nagasai Yalavarthi, Ali Awad, Shaheena Raheem, Ahmet Afsin Oktay

  • July 8, 2026

Related Content

Transitioning from hand-sewn to circular stapled cervical anastomosis after minimally invasive esophagectomy: a Western centre propensity score matching analysis

Mesenchymal R-spondin 3 promotes an immunogenic tumor microenvironment with adaptive immune resistance in human gastric adenocarcinoma

Correction: Editorial: Advancements in meningioma management: from imaging techniques to personalized medicine approaches